Day: August 14, 2025

— Arcadia revenues increase 11% year over year driven by 24% growth in Zola® — — Arcadia receives 2.7 million shares of stock in ABVE — — Arcadia eliminates $1M in liabilities — DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. “We are very pleased with our performance for the second quarter of 2025,” said T.J. Schaefer, CEO of Arcadia. “While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once again surpassed the performance of the category. Our gross margins have now exceeded 30% for ten straight quarters, while our underlying operating...

– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine’s path to approval for schizophrenia in Q4 2025; potential NDA submission targeted for Q2 2026 – CUPERTINO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in...

Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2025 operating and financial results and reviewed recent business highlights. “We are proud to enter the second half of the year with strong momentum as we have achieved all of our key milestones to date including advancing tegoprubart in kidney, islet cell (type 1 diabetes), and liver allotransplantation, as well as in xenotransplantation....

SAN JOSE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended June 30, 2025. As of June 30, 2025, the Fund’s net assets were approximately $0.7 million, or $0.11 per share, compared with net assets of approximately $0.8 million, or $0.12 per share as of March 31, 2025. As of June 30, 2025, the Fund’s portfolio included public and private securities valued at approximately $0.7 million, or $0.10 per share, which includes approximately $0.07 per share in cash and cash equivalents. Portfolio Summary (as of 6/30/25)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $0.22 million $0.03Cash/Cash Equivalents $0.51...

HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) —  KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a Bitcoin-Plus Treasury company that builds a portfolio of frontier technology businesses ranging from high performance energy systems to AI Robotics, today reported results for the second quarter ended June 30, 2025. “KULR is in its strongest financial position to accelerate its growth and continue its innovations,” commented KULR CEO Michael Mo. “Alongside the increased revenue in Q2, our Bitcoin holdings provide a solid financial balance sheet that enables us to invest confidently in developing new KULR ONE battery products, expand our R&D efforts, and drive towards the next phase of our growth.” Second Quarter 2025 Financial Results Revenues: In the second quarter...

LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced its financial results for the second quarter ended June 30, 2025. Key Financial Highlights: Operating Results for the Three Months Ended June 30, 2025:Net sales for three months ended June 30, 2025 were $2.56 million, a decrease of 5% from $2.69 million in the same period of 2024. Gross profit was $1.28 million compared to $1.19 million in the same period of 2024. Net loss was ($289 thousand), compared to ($536 thousand) loss in the same period of 2024.Operating Results for the Six Months Ended June 30, 2025:Net sales for the six months ended June 30, 2025 were $5.19 million, an increase of 3% from $5.06 million in the same period 2024. Gross profit was $2.49 million, compared to $2.21 million...

~ Q2 Gross Margin Expansion, Cost Reductions, Strategic Transactions, and Diversified Revenue Initiatives Could Position Super League to Achieve Adjusted EBITDA Positive in Q4 ~ ~ Company Advances Key Financial Initiatives and Broadens Revenue Mix ~ SANTA MONICA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE), a leader in engaging audiences through playable media, content, and experiences within mobile games and the world’s largest immersive platforms, today released second quarter 2025 financial results. Super League Chief Executive Officer, Matt Edelman Commented: “Our second quarter marked a pivotal step forward for Super League as we streamlined our operations, executed key financial transactions, launched innovative partnerships, and re-aligned the company’s focus toward reaching sustainable profitability....

Raises $30 Million From Oversubscribed Offering and Eliminates Debt & Obligations VIRGINIA CITY, Nev., Aug. 14, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our,” and the “Company”), today announced its second quarter 2025 results, business updates and an updated 2025 business outlook. Recent Corporate Liquidity and Capital Resources EventsClosed the initial $20 Million of Series A Investment and completed the separation of Fuels into Bioleum Corporation; Raised $30 million in gross proceeds to fully fund and accelerate the commercialization of its R2v3/RIOS Responsible Recycling certified zero-landfill industry-scale solar panel recycling facilities, each capable of recycling over 3.3 million panels per year, and to eliminate debts and advance additional site selections and other key development initiatives; Paid...

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. “The second quarter of 2025 marked steady execution and progress on our key strategic initiatives:  clinical development of our radiotherapeutic and the advancement of our diagnostic platform technologies toward commercialization,” said Marc H. Hedrick, M.D., Plus Therapeutics President...